Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2013, Article ID 285795, 6 pages
http://dx.doi.org/10.1155/2013/285795
Clinical Study

Aged Garlic Extract Improves Adiponectin Levels in Subjects with Metabolic Syndrome: A Double-Blind, Placebo-Controlled, Randomized, Crossover Study

1Dirección de Investigaciones, Fundación Oftalmológica de Santander (FOSCAL), Torre Milton Salazar, Primer Piso, Calle 155A No. 23-09, El Bosque, Floridablanca, Santander, Colombia
2Instituto de Investigaciones, Escuela de Medicina, Universidad de Santander (UDES), Bucaramanga, Colombia
3Departamento de Fisiología, Facultad de Medicina, Universidad Complutense de Madrid, Spain

Received 10 January 2013; Accepted 31 January 2013

Academic Editor: Giuseppe Valacchi

Copyright © 2013 Diego Gómez-Arbeláez et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background. Garlic (Allium sativum) has been shown to have important benefits in individuals at high cardiovascular risk. The aim of the present study was to evaluate the effects of the administration of aged garlic extract (AGE) on the risk factors that constitute the cluster of metabolic syndrome (MS). Methods and Design. Double-blind, crossover, randomized, placebo-controlled clinical trial to assess the effect of 1.2 g/day of AGE (Kyolic), for 24 weeks of treatment (12 weeks of AGE and 12 weeks of placebo), on subjects with MS. Results. The administration of AGE increased the plasma levels of adiponectin ( ). No serious side effects associated with the intervention were reported. Conclusion. The present results have shown for the first time that the administration of AGE for 12 weeks increased plasma adiponectin levels in patients with MS. This suggests that AGE might be a useful, novel, nonpharmacological therapeutic intervention to increase adiponectin and to prevent cardiovascular (CV) complications in individuals with MS.